Investor Presentaiton
Investor Presentation
First six months of 2018
Novo Nordisk volume market share is now ~36% of the
basal insulin market in the USA
Weekly TRx volume market shares* in the USA
-
glargine U100
Basal volume
TRX MS*
NN Total Basal
TresibaⓇ
LevemirⓇ
glargine U300
biosimilar glargine U100
70%
60%
50%
40%
30%
20%
10%
0%
Apr
2016
39.4%
35.8%
22.7%
12.8%
10.4%
8.2%
Jul
2018
Note: The graph does not show NPH, which accounts for the residual market share
Source: IQVIA weekly Xponent Plantrak (*excludes Medicaid), 6 Jul 2018
TRX volume: Insulin volume in mega units (MU) associated with total number of prescriptions;
VANTAGE FingerTip Formulary bridge, Jul 2018
MS: Market share
Medicaid represents ~12% of retail basal market volume
Slide 8
TresibaⓇ launch in the USA
TresibaⓇ volume market share is now around 13%.
TresibaⓇ has gained around 3% market share since the
beginning of 2018
TresibaⓇ formulary access is above 80% for
Commercial and Medicare Part D combined
Main market share driver in first half of 2018 has been
the formulary change at CVS part D
In mid-April 2018, promotional activities were initiated
to promote the updated TresibaⓇ label, including a
40% reduction of severe hypoglycaemic events
compared to insulin glargine U100.
novo nordiskView entire presentation